Scilex Holding Co has received a delisting notice from Nasdaq after failing to maintain the minimum market value required for continued listing. This notification, issued on November 17, 2026, indicates that the company’s market value fell below $35 million for 30 consecutive business days. This situation is significant as it may impact Scilex's operations and investor confidence.
Scilex, classified under the SIC code 2836, is involved in the biological products sector, specifically focusing on products not classified as diagnostic substances. The company trades on the Nasdaq under the ticker symbols SCLX for its common stock and SCLXW for its warrants. The recent filing, dated November 20, 2026, sheds light on the challenges the company is facing.
According to the filing, "The Notice has no immediate effect on the listing or trading of the Company’s common stock, par value $0.0001 per share, or the Company’s publicly-traded warrants to purchase Common Stock, which continue to trade on the Nasdaq Capital Market under the symbols 'SCLX' and 'SCLXW,' respectively." This indicates that while the company has received a warning, its stocks remain active on the exchange for now.
This delisting notice may affect various stakeholders, including investors, employees, and partners. Investors may be concerned about the company's financial health, while employees might face uncertainty regarding job security. Partners in the industry may also reassess their collaborations or investments in Scilex as the company navigates this challenge.
Looking ahead, the filing does not specify what steps Scilex will take in response to this notice. The company may need to explore options to improve its market value or consider alternative strategies to comply with Nasdaq's listing requirements.
Read Next
Alps Group Regains Compliance with Nasdaq Listing Standards
Ainos, Inc. Receives Nasdaq Delisting Notice Over Equity
Compass Therapeutics Receives Nasdaq Deficiency Notice
60 Degrees Pharmaceuticals Faces Nasdaq Delisting Risk
Biofrontera Inc. Faces Nasdaq Delisting Due to Low Stock Price
Senti Biosciences dismisses KPMG, appoints new auditor KNAV










